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Abstract 
Insulin-like growth binding protein-related protein 1 (IGFBP-rP1) has decreased expression in 
various tumors, but the role of IGFBP-rP1 in lung cancer has not yet been elucidated. In this 
study, we evaluated the IGFBP-rP1 expression in lung cancer cell lines and we found a 
reduced expression of IGFBP-rP1 at both mRNA and protein levels. In a tissue microarray 
containing 138 primary tumors analyzed by immunohistochemistry, 58 cases (42%) exhibited 
no expression of IGFBP-rP1, additionally, an association between IGFBP-rP1 expression and 
tumor gradings was found in squamous cell lung cancer. Neither deletion or gene 
rearrangement nor loss of heterozigosity was responsible for the inactivation of IGFBP-rP1. 
However, 5-aza-2'-deoxycytidine treatment restored the expression of IGFBP-rP1 in 3 out of 
4 lung cancer cell lines. Sequencing of sodium bisulfite–treated genomic DNA from these 3 
lung cancer cell lines revealed a heterogeneous methylation pattern in the region of exon 1 
and intron 1. Stable transfection of IGFBP-rP1 full-length cDNA into a lung cancer cell line 
H2170 led to an increased protein expression of IGFBP-rP1. IGFBP-rP1 positive transfectants 
remarkably reduced the ability of colony formation in soft agar, suppressed the tumor growth 
rate in nude mice and increased the number of apoptotic cells as well as the expression level 
of casepase-3 compared to controls. Moreover, treatment with differentiation modulating 
agent 5-bromodeoxyuridine (BrdU) led to an enhanced expression of IGFBP-rP1 in lung 
cancer cells. Out data suggest that IGFBP-rP1 is a tumor suppressor possibly via DNA 
methylation and induction of apoptosis in human lung cancer.
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Introduction 
The insulin-like growth factor (IGF) signalling pathway plays a key role in regulating 
proliferation, differentiation, and apoptosis in mammalian organisms (1). The IGF system is 
made up of a series of members including IGF-I, IGF-II, IGF receptor-I, IGF receptor-II, 
IGFBPs (IGFBP-1 to 6), IGFBP-rPs (IGFBP-rP1 to 10), and IGFBP proteases. IGFBP-rP1, 
also named mac25, tumor-derived adhesion factor, prostacyclin-stimulating factor or IGFBP-
7, was initially identified to be differentially expressed in normal leptomeningeal and 
mammary epithelial cells compared to their counterparts (2,3). IGFBP-rP1 shares about 30% 
identity at the amino acid level with the IGFBPs, but exhibits low affinity with IGFs, with a 
5- to 6-fold lower affinity for IGF-I and a 20- to 25-fold lower affinity for IGF-II, in 
comparision to IGFBP-1 to 6  (4-6).  
Although the biological roles of IGFBP-rP1 have not been well established, a study about the 
characterization of the normal distribution of IGFBP-rP1 showed that the protein has a highly 
restricted pattern of expression within a given tissue, allowing the analysis of changes in 
corresponding neoplasms (7). Indeed, a growing body of evidence suggests that IGFBP-rP1 
may act as a tumor suppressor in various cancer types. For example, the expression of IGFBP-
rP1 was found to be reduced in uterine leiomyomata compared with adjacent myometrium (8). 
Decreased IGFBP-rP1 expression was observed in prostate cancer and the restoration of 
IGFBP-rP1 expression by transfecting it into prostate cancer cell lines was shown to 
dramatically reduce tumorigenic potential of the cell lines (9,10). In breast cancer, IGFBP-rP1 
was implicated as a senescence-associated factor, and moreover, the downregulation of 
IGFBP-rP1 was found to be associated with inactivation of the retinoblastoma protein, cyclin 
E overexpression and increased proliferation of breast cancer cells (3,11-12). In liver cancer, 
diminished expression of IGFBP-rP1 was explained by promoter hypermethylation (13).   
Previously, we performed suppression subtractive hybridization (SSH) to identify lung 
cancer-associated genes when comparing gene expression between human bronchial epithelial 
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cells (HBEC) and lung cancer cell lines (14,15). Several cDNA libraries enriched for genes 
that were downregulated or upregulated in lung cancer cell lines were established. The clone 
HBEC383 isolated from the library containing the genes underexpressed in lung cancer, 
shared high similarity to human IGBFP-rP1. As the expression of IGFBP-1 to 6 has been 
shown to be modified in lung cancer (16,17), while little is known about the possible tumor-
inhibitory roles of IGFBP-rP1 in lung cancer, we are particularly interested in looking at the 
expression pattern as well as the biological role of IGFBP-rP1 in lung cancer. In this study, 
we analyzed the expression of IGFBP-rP1 in lung cancer cell lines and in primary lung tumors, 
explored the mechanism responsible for the downregulaton of IGFBP-rP1, and investigated 
the possible biological function of IGFBP-rP1 in human lung cancer.   
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Materials and Methods 
 
Cell lines and primary cell culture 
Human bronchial epithelial cells (HBEC) and human small airway epithelial cells (SAEC) 
were purchased from Clonetics (San Diego, CA) and cultured in BEG or SAB media 
(Clonetics) until population doubling of maximal 10. Human lung carcinoma cell lines 
including small cell lung carcinomas (SCLCs: COLO668, COLC677, H526, DMS79, H82, 
SHP77, CPC-N) and non small cell lung carcinoma (non-SCLCs: H2170, H125, H123, 
H2030, H226, BEN, H2228, H23) were bought from the American Type Culture Collection 
(ATCC, Rockville, MD) or from the German Collection of Microorganisms and Cell Culture 
(DSMZ, Braunschweig, Germany). Additionally, 4 NSCLC cell lines, D51, D54, D97 and 
D117 were established in our lab. They were derived from primary tumors of patients who 
were operated at the Charité University Hospital. These cells were grown in Leibovitz 15 
media supplemented with 10% FCS and 1% glutamine.  
 
Treatment of demethylation agent 5-aza-2’-deoxycytidine (5-aza-dCyd) 
To investigate the effect of demethylation agent 5-aza-2’- deoxycytidine (Sigma Chemical 
Co., St. Louis, MO), four lung cancer cell lines including H2170, H226, SHP77 and H2030 
lacking the expression of IGFBP-rP1 were selected for demethylation test. Cells were seeded 
at a density of 9 x 105 in 100-mm dishes until 50% confluency was achieved and were treated 
with 0, 10, 20 25 µM 5-aza-dCyd for 48 hours. Then the cells were washed with phosphated-
buffered saline (PBS) and incubated further in fresh medium containing the same 
concentration of 5-aza-dCyd for 48 hours before isolation of total RNA. The gene expression 
level was measured by RT-PCR as described below. 
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Evaluation of DNA methylation by sequencing of sodium bisulfite–treated DNA 
Treatment of genomic DNA from lung cancer cell lines with sodium bisulfite was performed 
as described previously (18). Bisulfite-treated DNA was subjected to PCR, resulting in a PCR 
product of 186-bp (+464 to +649) spanning 19 CpG sites of exon 1 and intron 1 region. The 
target fragment was amplified using the primer pair: 5’-
GGGGAGAAGGTTATTATTTAGGTTAGTAA-3’ (sense) and 5’- 
CCCTCCCATCTAACTCCTAAAATAC-3’ (antisense). The PCR conditions were as 
follows: 95°C for 15 minutes, 36 cycles of 95°C for 1 min, 54°C for 1 min and 72°C for 1 min, 
with final extension at 72°C for 10 minutes. PCR products were subcloned into the T/A 
cloning vector pCR2.1 (Invitrogen, Karlsruhe, Germany) and then sequenced with M13 
reverse primer as previously described. 
 
Modification of lung cancer cell lines with differentiation inducing agent, 5-
bromodeoxyuridine (BrdU). 
To study the role of IGFBP-rP1 in lung cancer differentiation, three lung cancer cell lines, 
H2228 (NSCLC), COLO668 (SCLC) and H526 (SCLC), were treated with differentiation 
inducing agent BrdU.   
Adherent cells of H2228 and COLO668 were seeded at a density of 9 x 105 in 10 mm dishes . 
Twenty-four hours later, H2228 cells were treated with 0, 10 and 20 µM BrdU, while for 
COLO668 the working concentrations of BrdU were 0, 0.1 and 0.5 µM according to the cell 
growth curve (data not shown).    
The floating SCLC cell line H526 was treated with 2.5 µM BrdU for 8 weeks. BrdU treatment 
led to the appearance of substrate-adherent cells. The floating cells were aspirated and the 
adherent cells, called H526B, were grown in the absence of BrdU. Afterwards, cells were 
harvested and RNA was isolated for RT-PCR and Western blot analysis.  
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DNA fingerprinting 
Genomic DNA was isolated from the cultured cell lines H526 and H526B according to 
standard protocol (proteinase K digestion, phenol/chloroform extraction, and ethanol 
precipitation). DNA fingerprinting was carried out with the random amplified polymorphic 
DNA (RAPD) method (19). PCR products were resolved by electrophoresis on a 1.5% (w/v) 
agarose gel and visualized by ethidium bromide staining.   
 
Northern blot analysis 
Ten µg of total RNA extracted from HBEC, SAEC, and lung tumor cell lines (H2170, D54, 
H125, H123, SHP77, H2030, D117, D51, D97, CoLo677, CoLo668, H82, BEN, H226, 
DMA79 and H526) were separated in 1.2% agarose/2.2 M formaldehyde gel and run for 4 hr 
at 60V followed by capillary transfer onto nylon membranes (Amersham, Braunschweig, 
Germany) overnight. A Northern blot of poly (A)+ RNA from different human tissues 
(Human 12-lane MTN blot, #7780-1) was obtained from Clontech (Germany). The cDNA 
clone of HBEC383 was amplified by nested PCR as described previously (15) and used as 
probe labeled by random priming with [32P]-dCTP (Megaprime labelling, Amersham). 
Following at least 30 min of prehybridization with Expresshyb solution (Clontech), the 
denatured probe was added and hybridization was carried out at 58°C overnight. Blots were 
washed with 2x SSC/0.1% SDS at room temperature and 0.1x SSCP/ 0.1% SDS at 60°C and 
exposed to X-ray films at –80°C. 
 
Semi-quantitative RT-PCR 
Total RNA was prepared from the HBEC, SAEC, and lung tumor cell lines by using Trizol 
(Life Technologies, Gaithersburg, MD) and then incubated with RQDNaseI (Progema, 
Madison, WI) for 40 min at 37°C. 
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First-strand cDNA was reverse-transcribed by 200 U superscript II transcriptase (Gibco, 
Eggenstein, Germany) from 2 µg of total RNA, in the presence of 1× RT buffer, 100 mM 
DTT, 20 U RNase inhibitor and 5 mM dNTPs, using the random hexamer primers supplied in 
the kit according to manufacturer’s protocol. Reactions lacking reverse transcriptase were 
used to verify the absence of amplification from genomic DNA contamination (data not 
shown). The following primers were used for PCR amplification: IGFBP-rP1 primers 
(forward: 5 -CATCACCCAGGTCAGCAA -3  and reverse: 5 - 
TGGAGGTTTATAGCTCGG -3 ); caspase 3 primers (forward: 5'-
CAAACTTTTTCAGAGGGGATCG-3'; caspase-3 reverse, 5'-
GCATACTGTTTCAGCATGGCA-3'. PCR conditions were 94°C 1 min, 52°C 30 sec and 
72°C 30 sec, for 33 cycles, with initial denaturation at 95°C 5 min and final elongation at 
72°C 5 min. Controls were performed with commercially available glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) primers (Clontech).  
Tumor tissues 
Tumor specimens from 138 patients with lung cancer were used for construction of tissue 
microarrays.  In addition, 29 paired normal/tumor tissues were applied for the analysis of loss 
of heterozygosity (LOH). All of these patients were undergoing surgical operation of lung 
cancer at the Department of Surgery of Charité University Hospital from 1995 to 2000. No 
adjuvant radiotherapy or chemotherapy was administered before surgery. For LOH analysis, 
the specimens were frozen in liquid nitrogen and stored at -80°C before genomic DNA 
isolation. The clinicopathological characteristics of the samples were listed in Table 1 
according to TNM criteria of the UICC (20).  
Tissue microarray construction and immunohistochemical analysis  
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Tissue microarrays (TMAs) were constructed with assistance of Oligene (oligene GmbH, 
Berlin, FRG) using a manual tissue arrayer purchased from Beecher Instruments (Woodland, 
USA). All sections were reviewed by two pathologists (T Knösel and YW Yu). Suitable areas 
for tissue retrieval were marked on standard haematoxylin and eosin (H&E) sections. Tissue 
cylinders with a diameter of 0.6 mm were punched out of the paraffin block and transferred 
into a recipient array block. After construction, 4 µm sections containing 276 tumors from 
138 patients were cut from the donor  blocks and transferred to glass slides without any 
sectioning aids. 
Immunohistochemistry was carried out as described previously (18). Polyclonal rabbit anti-
IGFBP-rP1 antibody (Immunological & Biochemical testsystems GmbH, Germany) was used 
at 1:200 dilution. Three large sections from normal lung tissue were used as controls. All 
slides were manually read by one pathologist (T Knösel) who was blinded to the clinical 
information. Immunohistochemistry was scored semiquantitatively as negative (score 0), 
weak (score 1), moderate (score 2) or strong (score 3) as previously described. For statistical 
evaluation, scores 0-1 were therefore considered as negative and scores 2-3 as positive. 
LOH analysis  
Twenty-nine paired samples of tumor and normal DNA were assessed for allelic loss by 
microsatellite polymorphism analysis. Three microsatellite markers including D4S189 (4p15-
q23), D4S231 (4q11-q31) and D4S392 (4q12-q12) were chosen for LOH analysis. Primer 
sequences were obtained from the genome database and commercially synthesized (MWG-
Biotech, Ebersberg, Germany). For LOH-analysis, one primer was labelled with the IRD700 
infrared dye. PCR was performed as previously described and the DNA fragments were 
finally visualized by non-radioactive detection (19). LOH was determined when the allele of 
the tumor sample was less than 50% in comparison to the normal DNA.   
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Construction of expression vector and transfection 
IRES 2 neo expression vector containing the full-length coding sequence of IGFBP-rP1 was 
constructed as previously described (9). The IRES 2 neo/IGFBP-rP1 expression vector was 
digested with EcoR I and Kpn I, afterwards, the 1.1- kb fragment of the IGFBP-rP1 insert was 
subcloned into an EcoR I/Kpn I restriction site of the mammalian expression vector 
pcDNA3.1 (Invitrogen).  
To obtain stable transfectants, lung cancer cells H2170 were seeded at a density of 9 x 105 
cells in 100-mm dishes, cultured for 24 hours, and transfected with 8 µg of 
pcDNA3.1/IGFBP-rP1 and 40 µg of lipofectin (Invitrogen) according to the manufacturer's 
recommendation with a slight modification. Empty vector was transfected as a control. β-
galactosidase was assayed to control transfection efficiency. Forty-eight hours after 
transfection, G418-resistant clones were selected by the addition of G418 at 0.4 mg/ml to the 
culture medium for 2 to 3 weeks.  
 
Western blot analysis 
Western blot analysis was performed to detect IGFBP-rP1 in cultured media or in cell lysates. 
Briefly, media from cells were collected and normalized based on cell counts and then 
concentrated by filtration through nitrocellulose (Milipore, Germany). After concentration, 
proteins were redissolved in 50 µl of SDS sample buffer containing 0.5 M Tris (pH 6.8), 1% 
SDS, 10% glycerol, 0.003% bromphenol blue and 8 M urea by heating for 10 min at 95°C. 
Proteins from cell lysates were isolated according to standard protocol. Samples were 
electrophoresed on 12% SDS-polyarcylamide gels and electroblotted onto nitrocellulose. 
Polyclonal anti-IGFBP-rP1 antibody was used at a 1:1000 dilution. Signal was visualized 
with alkaline horseradish peroxidase–conjugated goat anti-rabbit antibody (1:1000; DAKO, 
Hamburg, Germany) and enhanced chemiluminescence detection system (Amersham, 
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Freiburg, Germany) according to standard procedures. As loading control, rabbit anti-actin 
antibody was used at a concentration of 1:1000 (Chemicon). 
Soft Agar Assay 
To analyze anchorage-independent growth of IGFBP-rP1 transfectants and control empty 
vector-transfected H2170 cells, 40-mm dish was first layered with 1% agar/2X RPMI with 
10% FCS. A top layer containing 15 x 103 cells/dish suspended in 2x RPMI supplemented 
with 10% FCS and 0.5% agar was added. Assays were performed in duplicate. Colonies were 
counted 4 weeks after seeding in soft agar.    
Tumorigenecity assay 
For testing tumorigenicity in nude mice, suspensions of 1 x 106 cells from the two IGFBP-rP1 
transfectants N6 and N10, the empty vector transfectant M12 as well as the parental cell line 
H2170 in a volume of 0.2 mL of serum-free culture medium were injected s.c. into 5- to 8-
week-old female immune-deficient nude mice (Shoe:NMRI-nu/nu) purchased from Charles 
River Laboratories (Massachusetts, USA). Mice were divided into 4 groups according to the 4 
cell lines tested. Each group contained three mice which received the injection of the same 
cell line. Mice were then monitored weekly for tumor formation for 8 weeks. If tumors were 
present, tumor volume was calculated using the formula: (l x w2)/2 (where l = length and w = 
width of tumor). Cell populations were considered to be nontumorigenic if no tumors were 
detected after 5 months postinjection.  
Apoptosis assay  
Starved cells of H2170, IGFBP-rP1 transfectants N6 and N10 and control empty vector-
transfected cells M12 were seeded in 96-well plates (3000 cells/well) and cultured in 200 µl 
RPMI serum-free medium. After 72 h, cultured medium was replaced with fresh RPMI 
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medium containing APOPercentage Dye Label (Biocolor Ltd., United Kingdom) and 
incubated for 30 min at 37°C. Purple-red stained cells were identified as apoptotic cells and 
the number of apoptotic cells/100 cells was counted. 
Statistical analysis 
To compare the protein expression of IGFBP-rP1 with clinicopathologic parameters, 2 x 2 
contingency tables (e.g. IGFBP-rP1 negative and IGFBP-rP1 positive and G1&G2 versus G3) 
were set up and the 2 test was applied. For apoptosis assay, the number of apoptotic cells 
between IGFBP-rP1 transfectant and controls was calculated by using the Student’s t test. All 
analyses were done using the statistical software package SPSS 11.5 and P values <0.05 were 
considered statistically significant.  
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Results 
Expression analysis of IGFBP-rP1 in cultured lung cancer cell lines 
IGFBP-rP1 mRNA expression was analyzed in 19 lung cancer cell lines by using Northern 
blot analysis together with RT-PCR (Fig. 1A, 1B). We found that IGFBP-rP1 was 
downregulated in most of the lung cancer cell lines tested compared to normal controls of 
HBEC and SAEC. Especially for the cell lines H2170, H125, SHP77, H2030, D117, H82, 
BEN, H226, DMS79 and H526, there was no clear signal detectable. In good agreement with 
mRNA expression of IGFBP-rP1, Western blot analysis showed that IGFBP-rP1 protein 
expression markedly decreased or lost in lung cancer cell lines of COLO677, H526, H2170, 
COLO668 and H2228 (Fig. 1C).      
Expression analysis of IGFBP-rP1 in lung primary tumors 
A tissue microarray was constructed to explore the IGFBP-rP1 protein expression in 276 
primary lung cancer samples representing 138 patients. Figure 2A shows one section of the 
TMA. In the tumor samples, 58 cases (42%) exhibited no relevant IGFBP-rP1 staining (Fig. 
2B), while in the other 80 cases (58%), the IGFBP-rP1 staining was positive with the signals 
localizing in cytoplasm (Fig. 2C-E). The expression of IGFBP-rP1 did not differ significantly 
by tumor stage, tumor size and nodal status. However, there was a correlation between 
decreased IGFBP-rP1 expression and tumor gradings (G1 and G2 versus G3) in squamous 
cell lung cancer. The tumors with higher grading exhibit lower expression of IGFBP-rP1 
protein, reaching statistical significance (p = 0.029). 
On analyzing of 65 lung cancer patients with a median 24 months survival (range 2-66 
months), we found no significant effect of IGFBP-rP1 protein expression on overall survival 
(p= 0.30; Kaplan-Meier statistical analysis). 
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LOH analysis 
LOH analysis was carried out in 29 paired normal lung and tumor tissues. We found that for 
the microsatellite marker D4S189, LOH occurred in 4 out of 23 informative cases, similarly, 
for the marker D4S231 and D4S392, only 2 and 3 cases respectively, exhibited LOH (data not 
shown).   
 
Reexpression of IGFBP-rP1 in lung cancer cell lines after 5-aza-dCyd treatment 
To investigate whether the lack of expression of IGFBP-rP1 in tumor cells is associated with 
DNA hypermethylation, we treated four cell lines including H2170, H226, SHP77 and H2030 
with increasing concentrations of the DNA methyltransferase inhibitor 5-aza-dCyd and 
measured IGFBP-rP1 mRNA expression by RT-PCR. As shown in Fig. 3, the expression of 
IGFBP-rP1 was restored in three cell lines of H2170, H226 and SHP77. In H2170, 
reexpression increased with rising concentration of 5-aza-dCyd. Compared to H2170, the 
reexpression of IGFBP-rP1 in H226 and SHP77 was, however, not in a dose-dependent 
manner.   
Analysis of the methylation status in lung cancer cell lines 
The methylation status of the IGFBP-rP1 gene in lung cancer was determined by PCR after 
bisulfite treatment of DNA followed by sequencing of the PCR products. We amplified a 186-
bp fragment in the region of exon 1 and intron 1 spanning 19 CpG sites and analyzed the 
methylation status in 20 colonies from the lung cancer cell line H2170, H226 and SHP77 
respectively. The target fragment of 186-bp was only observed in bisulfite treated genomic 
DNA but not in the unmodified DNA, indicating a successful modification of the DNA by the 
bisulfite treatment (Fig. 3B). Sequencing analysis showed that methylation occurred in all 
three cell lines and all the colonies analyzed, among which a heterogeneous methylation 
pattern was found (Table 2). The hotspots sites were concentrated on +541, +544, +548, +556, 
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+569, +581 and +586. Compared to cell line H2170 and H226, methylation occurred most 
frequently in cell line SHP77. Additionally, for normal cells of HBEC, we randomly picked 
out 10 colonies for sequencing, but did not find any methylation within the CpG dinucleotides. 
 
Characterization of Stable Transfectants 
To further examine the possible biological role of IGFBP-rP1 in lung cancer, we transfected 
the tumor cell line H2170 with the mammalian expression vector pcDNA3.1/IGFBP-rP1 
containing the whole coding region of the gene. Colonies showing resistance against G418 
were selected and further characterized. IGFBP-rP1 expression in different clones was 
measured by Western blotting (Fig. 4A). We selected two IGFBP-rP1 transfectants named N6 
and N10 which showed higher expression of IGFBP-rP1 compared to mock transfectant 
(empty vector) and the parental cell line H2170 for the soft agar test, tumorigenecity assay 
and apoptosis assay.  
Effect of IGFBP-rP1 on anchorage-independent growth of transfected and control Cells.  
In soft agar test, we observed a reduced capacity of IGFBP-rP1 transfectants N6 and N10 to 
form colonies compared to mock transfectant and parental cells. After 4 weeks of incubation 
in soft agar, fewer colonies as well as smaller size of colonies formed by the transfectants N6 
and N10 compared with the control clones and parental cells (Fig.4B).    
Tumor formation in vivo 
Mice were monitored weekly for tumor formation over an 8-week period. Mice that were 
given injection of the IGFBP-rP1 transfectants had lower tumor growth rate compared to 
those receiving the injection of mock transfectant or parental tumor cells (Fig. 4C). Especially 
for the IGFBP-rP1 positive transfectant N10, no tumor developed in each of 3 mice after 8 
weeks. The mice were further observed for 3 months, however, still no tumor grew. 
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Effect of IGFBP-rP1 expression on apoptosis of H2170 cells. 
To elucidate a potential influence of IGFBP-rP1 on apoptosis in human lung cancer cells, we 
performed APOPercentage assay to determine the relationship between IGFBP-rP1 expression 
and apoptosis in the IGFBP-rP1 cDNA-transfected H2170 cells, control empty vector and 
parental cells. As shown in Fig. 5A and 5B, the number of apoptotic cells which stained 
purple-red in the IGFBP-rP1 transfectant N10 (42 of 100 cells) was significantly higher than 
that in mock transfected cells (8 of 100 cells) or parental cells (4 of 100 cells). For the other 
IGFBP-rP1 transfectant N6, the number of apoptotic cells was slightly higher (10 of 100 cells) 
than in control, which however did not reach statistical significance.  
To further confirm the role of IGFBP-rP1 in apoptotic lung cancer cells, we analyzed the 
mRNA expression of caspase-3 in IGFBP-rP1 transfectants N6, N10 and control cells. We 
found that caspase-3 was strongly expressed in transfectant N10 and slightly expressed in N6 
compared with controls (Fig. 5c). 
 
Effect of IGFBP-rP1 on lung cancer differentiation 
BrdU has been used to induce differentiation in a variety of tumor cell lines including 
melanoma, neuroblastoma and lung cancer cell lines (22-24). To elucidate the role of IGFBP-
rP1 in lung cancer differentiation, we established a differentiation cell-model by exposure of 
lung cancer cell lines including H2228, H526 and COLO668 to differentiation modulating 
agent BrdU. After that, the expression of IGFBP-rP1 was evaluated in the cell-model.  
Interestingly, a striking morphological difference between H526 and H526B turned out after 
BrdU modification. When cultured in vitro, SCLC cell line H526 grows as floating cell 
aggregates (Fig. 6A). After BrdU treatment, adherent cells termed H526 B appeared among 
the floating cells (Fig. 6B).  
DNA fingerprinting was carried out and we found that for all primer sets, distinctive banding 
patterns were detectable, however, for the same primer set, the DNA banding pattern between 
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H526 and H526B was identical (Fig. 6C). This result indicated that the subpopulation of 
H526B did not result from contamination by other adherent cells but was indeed induced by 
cell differentiation. H526 and H526 B were genetically identical.  
The utility of this cell-model was confirmed by analyzing the expression of several lung 
differentiation markers such as surfactant protein C, Connexin26 and PITX1 (data not shown). 
Afterward, RT-PCR and Western blotting were performed to analyze the expression of 
IGFBP-rP1 in the cell-model. It turned out that IGFBP-rP1 was upregulated at both mRNA 
and protein levels in cell line H2228 and H526 after BrdU treatment, suggesting the 
involvement of IGFBP-rP1 in lung cancer differentiation (Fig. 6D, Fig. 6E).   
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Discussion 
IGFBP-rP1 is distributed in a wide range of different human tissues, but its expression was 
reduced or lost in various tumor cell lines (9-13). In lung cancer, the functional role and 
regulatory mechanism(s) of IGFBP-rP1 have not yet been investigated. In this study, we 
analyzed the IGFBP-rP1 gene which was identified in our SSH screening for differentially 
expressed genes between human bronchial epithelial cells (HBEC) and a lung squamous 
cancer cell line H2170. It was of interest that IGFBP-rP1 was downregulated not only in the 
cell line H2170 used for the SSH library construction, but also was underexpressed in a panel 
of lung cancer cell lines tested. Considering its chromosomal location of 4q12, a region found 
to be frequently deleted in lung cancer, and its potential tumor suppressive functions in 
prostate cancer, breast cancer and liver cancer, we focused on the role of IGFBP-rP1 in lung 
cancer.  
We first analyzed the expression of IGFBP-rP1 in lung cancer cell lines as well as in primary 
lung tumors, and we found that IGFBP-rP1 expression was decreased in a majority of lung 
cancer cell lines at both mRNA and protein levels compared to normal control. In primary 
lung tumors, 58 out of 138 cases (42%) exhibited no expression of IGFBP-rP1 protein. This 
observation is in good agreement with those reported in breast, prostate and liver cancer, 
where IGFBP-rP1 was strongly expressed in normal tissues but downregulated in their 
counterparts. Moreover, a significant association between the IGFBP-rP1 protein expression 
and tumor gradings was found in squamous cell lung cancer (SCC). SCC patients with higher 
grading showed relatively low expression of IGFBP-rP1 protein suggesting the involvement 
of IGFBP-rP1 in lung cancer differentiation and progression.   
The mechanism of loss of IGFBP-rP1 expression in cancer cells is not fully understood, 
however, deletion, mutation or gene rearrangement is obviously not the common event for the 
inactivation of IGFBP-rP1, since so far no deletion, mutation or gene rearrangement of 
IGFBP-rP1 has been reported in any type of cancers. On the contrary, the loss of 
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heterozygosity of the IGFBP-rP1 gene is a frequent genetic event in breast cancer (25) and  
DNA hypermethylation of IGFBP-rP1 seems to be linked to its downregulation in prostate 
cancer and in hepatic carcinoma (9,13). In lung cancer, promoter hypermethylation of the 
IGFBP-3 gene, another member of the IGF superfamily, was thought to be responsible for the 
loss of the IGFBP-3 gene expression (26). To determine if genetic mechanisms participate in 
gene silencing, we performed LOH analysis as well as Southern blot analysis. No deletion or 
gene rearrangement was found and only very few cases showed LOH. The expression of 
IGFBP-rP1 was restored in 3 out of 4 lung cancer cell lines after they were exposed to 
demethylation agent, 5-aza-2'-deoxycytidine. The methylation status of IGFBP-rP1 was 
further evaluated by sequencing of sodium bisulfite–treated genomic DNA from the 3 lung 
cancer cell lines. A heterogeneous methylation pattern in IGFBP-rP1 turned out, lending 
support that 5-aza-dCyd–dependent increase of the IGFBP-rP1 gene expression occurs 
directly, not through effects at other loci, in a way that the IGFBP-rP1 gene expression is 
regulated by another protein that itself is methylated. Thus, the downregulation of IGFBP-rP1 
in lung cancer could be explained by DNA hypermethyation of CpG inlands. To our 
knowledge, this is the first report providing direct evidence of DNA hypermethylation of 
IGFBP-rP1 in cancer cells by sequencing of the bisulfite–treated genomic DNA.  
Early studies showed that overexpression of IGFBP-rP1 in prostate cancer cell lines resulted 
in increased doubting time, decreased colony formation and reduced tumor growth in nude 
mice (9,10). To investigate the function of IGFBP-rP1 in lung cancer, we stably transfected 
the lung cancer cell line H2170 with full-length cDNA of this gene. We selected H2170 for 
transfection based on three reasons. First, H2170 was applied for the construction of the SSH 
libraries. Second, there is no endogenous IGFBP-rP1 expression in H2170 which was 
confirmed by Northern blot and Western blot analysis. Third, treatment of H2170 with 5-aza-
2'-deoxycytidine restored the expression of IGFBP-rP1. After transfection, we found that the 
obtained transfectants N6 and N10 displayed high IGFBP-rP1 protein expression levels 
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correlated with impaired ability of anchorage-independent growth in vitro and suppression of 
tumorigenicity in nude mice, and moreover, increased the number of apoptotic cells through 
upregulation of the caspase-3 gene compared with the mock transfectant and cancer cells. 
Thus, expression analysis and in vitro as well as in vivo growth characteristics are compatible 
with a role of IGFBP-rP1 as a tumor suppressor in lung cancer. 
IGFBP-rP1 is a member of IGF superfamily with the exhibition of a low affinity to IGF-I and 
IGF-II. Although the influence of IGFBP-rP1 on the action of IGFs has been reported (27,28), 
the evidence suggesting a predominant IGF-independent role for IGFBP-rP1 is intensive. For 
example, Mutaguchi et al. found that the growth rate of transfected prostate cancer cells PC-3-
rP1 and control PC-3 cells did not change by treatment with IGF-I in the culture medium (9). 
Oh et al. treated Hs578 T cancer cells with baculovirus-expressed IGFBP-rP1 and observed 
that the treatment resulted in inhibition of DNA synthesis and cell proliferation in a dose-
dependent manner, even in the absence of IGF peptides (29). In the present study, we treated 
IGFBP-rP1 positive transfectants N6 or N10 as well as control cells with IGF-I, however, no 
change on the growth rate of the cells turned out (data not shown). Therefore, it seems likely 
that IGFBP-rP1 exerts its tumor suppressive function through IGF-independent pathway in 
lung cancer.  
Studies of IGFBP-rP1 and its ability to induce apoptosis independent of IGF in PC-3 and M12 
prostate cancer cells hint to a possible mechanism for IGFBP-rP1 as a tumor suppressor in 
other cancer cells (9,10). Additionally, the overexpression of the other two IGF superfamily 
members, IGFBP-3 and IGFBP-6, has been reported to inhibit the growth of non-small-cell 
lung cancer (NSCLC) cells by inducing apoptosis (30-32). Indeed, after transfection of 
IGFBP-rP1 into the lung cancer cell line H2170, we found that the number of apoptotic cells 
was significantly increased in IGFBP-rP1 positive transfectant N10 and correspondingly, N10 
cells showed more expression of caspase-3 mRNA compared to controls, raising the 
 21
possibility that IGFBP-rP1 has a tumor-suppressive activity through induction of apoptosis in 
lung cancer. 
IGFBP-rP1 was considered to induce neuroendocrine (NE) differentiation in interaction with 
a novel protein 25.1 in lung cancer and prostate cancer (33,34). Again, in prostate cancer, 
overexpression of the transcription factor SOX9 was thought to contribute to growth 
regulation by IGFBP-rP1 via inhibition of cell growth and promotion of differentiation (35). 
In the present study, we established a lung cancer differentiation cell-model by treating three 
lung cancer cell lines with the differentiation inducing agent BrdU. Exposure of SCLC cell 
line H526 to BrdU induced a phenotypic transition toward an epithelioid phenotype. This 
morphological transformation led to the development of an adherent monolayer (H526B) 
from spherical tightly aggregated cell –cell clusters of the non-substrate-adherent parental cell 
line (H526). Enhanced expression of IGFBP-rP1 was confirmed by RT-PCR and Western blot 
analysis in cell line H2228 and H526 after BrdU modification, indicating a role that IGFBP-
rP1 plays in the process of lung cancer differentiation. However, the precise function of 
IGFBP-rP1 in lung cancer differentiation still remains to be investigated.  
In summary, our data strengthen the observation that IGFBP-rP1 functions as a putative tumor 
suppressor gene via DNA methylation and induction of apoptosis in human lung cancer. The 
role of IGFBP-rP1 in apoptosis as well as in lung cancer differentiation could provide a 
potential novel therapeutic target in lung cancer. 
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Figure legends 
Figure 1. A, Northern blot analysis of IGFBP-rP1 mRNA from cultured normal epithelial 
lung cells (HBEC), normal small airway epithelial cells (SAEC) and lung cancer cell lines. 
IGFBP-rP1 mRNA was underexpressed in lung cancer cell lines in contrast to HBEC and 
SAEC. Lower panel: Control hybridization with β-actin. B, RT-PCR demonstrated the 
decreased expression of IGFBP-rP1 mRNA in lung cancer cell lines compared to HBEC and 
SAEC. N: Negative control (H2O as template). Lower panel: GAPDH was used as a positive 
control. C, Western blot analysis of IGFBP-rP1 protein expression in HBEC and lung cancer 
cell lines. Compared to HBEC, most of the lung cancer cell lines showed diminished 
expression of IGFBP-rP1. 
 
Figure 2.  Examples of IGFBP-rP1 protein expression in primary lung tumors. A section from 
TMA (A, 2.5 fold magnification); IGFBP-rP1 negative (B, 25 fold magnification); IGFBP-
rP1 weakly positive (C, 25 fold magnification); IGFBP-rP1 moderately positive (D, 25 fold 
magnification); IGFBP-rP1 strongly positive (E, 25 fold magnification). 
 
Figure 3. A, RT-PCR showed the rexpression of IGFBP-rP1 in lung cancer cell lines H2170, 
H226 and SHP77 after exposure to demethylation agent, 5-aza-2’-deoxycytidine. The 
concentration of 5-aza-2’-deoxycytidine was indicated. cDNA from HBEC was used as 
positive control (P). Lower panel: The integrity of RNA and cDNA was confirmed using 
GAPDH as positive control. B, PCR using the bisulfite modified genomic DNA isolated from 
HBEC, H2170, H226 and SHP77 as templates. In bisulfite treated DNA, a 186-bp target band 
of IGFBP-rP1 was found, while in unmodified DNA (N), there was no specific band 
detectable. 
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Figure 4. A, Western blot analysis of protein isolated from media. IGFBP-rP1 protein 
expression was found in cells of N6 and N10 stably transfected with full-length cDNA of 
IGFBP-rP1. In mock tranfectants (M12 and M18) as well as in parental cells H2170, no signal 
detectable. B, Colony formation assay. IGFBP-rP1 transfectants N6 and N10 showed reduced 
capacity to form colonies in soft agar compared to negative controls. C, Tumorigenicity assay 
in immune-deficient nude mice. IGFBP-rP1 transfectants N6 and N10 suppressed tumor grow 
rate in nude mice compared to controls. 
 
Figure 5. Effect of IGFBP-rP1 expression on apoptotic index of H2170 cells. A, Typical 
photographic demonstration of apoptotic cell count in IGFBP-rP1-positive clone of N10, 
mock transfectant M12 and parental cells H2170. B, The number of apoptotic cells in IGFBP-
rP1 transfectant N10 (42 out of 100) is higher than that in mock transfectant M12 (8 of 100) 
and parental cells H2170 (4 of 100 cells; p<0.001). C, Up-regulation of caspase-3 was 
observed in IGFBP-rP1 transfected cells of N10 compared to controls. 
 
Figure 6.  Role of IGFBP-rP1 in lung cancer differentiation. A, H526 cells were treated with 
BrdU as described under Materials and Methods to develop the stable adherent H526B cell 
line. Phase contrast micrograph of H526 cell aggregates in suspension. B, Phase contrast 
micrograph showing the epithelioid morphology of H526B cell monolayer. C, DNA 
fingerprinting of H526 and H526B cell lines showing the same DNA banding pattern between 
these two cells by using primer sets 4 and 5. D, IGFBP-rP1 was upregulated at mRNA level in 
the cell line H2228 and H526 after BrdU treatment. E, increased IGFBP-rP1 protein was 
observed in the cell line H2228 and H526 after BrdU modification.  
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Table 1. Study cohort. 
 
Table 2. Methylation patterns of IGFBP-rP1 from aberrantly methylated lung tumor cell lines. 
Sequencing of colonies from H2170, H226 and SHP77 revealed a heterogeneous methylation 
status. methylated CpG dinucleotides are indicated by closed circles; Open circles represent 
the unmethylated CpG dinucleotides;  
Table 3. Correlation between IGFBP-rP1 protein expression and clinicopathological data. 
Table 1 Study cohort
IGFBP-7 IGFBP-7
negative positive
n (%) n (%)
Total No (n = 138 ) 58(42%) 80(58%)
ADC 29(21%) 39(28%)
SCC 25(19%) 34(25%)
LCLC 2(1%) 5(4%)
SCLC 2(1%) 2(1%)
Grade 1-2 32(23%) 34(25%)
Grade 3 26(19%) 46(33%)
PT1 13(9%) 21(15%)
PT2+ 45(33%) 59(43%)
PN0 34(25%) 41(30%)
PN1+ 24(17%) 39(28%)
Stage I-II 38(28%) 54(39%)
Stage III-IV 20(14%) 26(19%)
ADC=adenocarcinomas; SCC=squamous cell carcinoma; LCLC=
large cell lung carcinoma; SCLC= small cell lung carcinoma
Table 2   Methylation patterns of IGFBP-rP1 from aberrantly methylated lung tumor cell lines. 
CpG position
Colonies
H2170-1 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-2 ● ● ○ ● ● ○ ● ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ●
H2170-3 ○ ○ ○ ○ ● ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
H2170-4 ○ ○ ○ ● ● ● ● ● ● ● ● ○ ● ○ ○ ○ ○ ○ ○
H2170-5 ○ ○ ○ ● ● ● ● ● ○ ○ ● ○ ● ○ ○ ○ ○ ○ ○
H2170-6 ○ ● ● ● ● ● ● ● ● ● ● ● ○ ○ ○ ○ ○ ○ ○
H2170-7 ○ ○ ○ ● ● ● ● ○ ● ● ● ○ ● ○ ○ ○ ○ ○ ○
H2170-8 ● ○ ○ ○ ● ○ ● ○ ● ○ ● ● ● ○ ○ ○ ○ ● ●
H2170-9 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-10 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-11 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-12 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-13 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-14 ○ ○ ● ● ● ● ● ● ● ○ ○ ○ ● ○ ○ ● ○ ○ ○
H2170-15 ○ ○ ● ● ● ● ● ● ● ○ ○ ○ ● ○ ○ ● ○ ○ ○
H2170-16 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-17 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-18 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-19 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H2170-20 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ○ ○ ○ ● ○ ○ ○
H226-1 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
H226-2 ○ ○ ○ ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-3 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-4 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-5 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-6 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-7 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-8 ○ ○ ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
H226-9 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-10 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-11 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-12 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-13 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-14 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-15 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-16 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-17 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ● ● ● ○ ○ ○
H226-18 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-19 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
H226-20 ○ ○ ● ● ● ● ● ● ● ● ● ○ ● ○ ○ ● ○ ○ ○
SHP77-1 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ○ ● ● ●
SHP77-2 ○ ○ ○ ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
SHP77-3 ● ○ ● ● ● ● ● ● ● ○ ● ● ● ○ ● ● ● ● ●
SHP77-4 ● ● ● ○ ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
SHP77-5 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
SHP77-6 ● ● ● ● ● ● ● ● ● ○ ● ● ● ○ ● ● ● ● ●
SHP77-7 ● ○ ● ○ ● ● ● ○ ● ● ● ● ● ● ● ● ● ● ●
SHP77-8 ● ● ● ● ● ● ● ○ ● ● ● ● ● ● ● ● ● ● ●
SHP77-9 ○ ○ ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
SHP77-10 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
SHP77-11 ○ ○ ● ● ● ● ● ● ● ○ ○ ○ ● ○ ○ ● ○ ○ ○
SHP77-12 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
SHP77-13 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
SHP77-14 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
SHP77-15 ○ ○ ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
SHP77-16 ○ ○ ● ● ● ● ● ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
SHP77-17 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
SHP77-18 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
SHP77-19 ○ ○ ● ● ● ● ● ● ● ○ ○ ○ ● ○ ○ ● ○ ○ ○
SHP77-20 ○ ○ ● ● ● ● ● ● ● ○ ● ○ ● ○ ○ ● ○ ○ ○
572 577544 548 556 569502 517 521 541 581 583 586 592 622597 599 611 620
Table 3   Correlation between IGFBP-rP1 expression and clinicopathological 
              data (p values*)
Stage (UICC) Grade pN+ pT
ADC 0.445 1,000 0.807 0.070
SCC 0.275 0.029 0.169 0.061
All tumours 0.856 0.168 0.489 0.691
*P values were calculated by Chi-square test
ADC = adenocarcinoma; SCC = squamous cell carcinoma
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